The head of US pharmaceutical conglomerate Pfizer defended plans to acquire UK rival AstraZeneca as Pfizer chief executive Ian Read spoke to a panel of British lawmakers about the deal.
”We don’t see any substantial antitrust issues on this deal anywhere in the world,” Read said.
The merger would mark the largest …read more
Source: Global Competition Law Blogs